A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MDS/MPN / myelodysplastic/myeloproliferative neoplasms

[Related PubMed/MEDLINE]
Total Number of Papers: 95
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MDS/MPN  (>> Co-occurring Abbreviation)
Long Form:   myelodysplastic/myeloproliferative neoplasms
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Chronic myelomonocytic leukemia diagnosis and management. AML, CMML, CPSS, GFM, HMAs, WHO
2021 Extramedullary myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with ring sideroblasts and thrombocytosis. ---
2021 Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. ASXL1, CI, EZH2, HR, NRAS, SETBP1, STAG2
2021 Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms. ---
2021 Isolated CNS relapse in FLT 3 mutation positive CMML post allogeneic stem cell transplant: Report of a rare case. ---
2021 Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms. MPN-U, NGS
2021 The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens. AML, CML, MDS, MPN
2021 The relationship between serum ferritin level and fibrosis and splenomegaly in myelofibrosis. MF
2021 Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes. ---
10  2020 A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: a case report and literature review. aCML
11  2020 Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. aCML, AP
12  2020 ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. AML-MRC, AML-NOS, MDS
13  2020 Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. AML, CMA, CN-LOH, MDS
14  2020 Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. AML, MDS, MPN
15  2020 Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. aCML, Ph
16  2020 Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy. FCIP, MDS, Non-MDS
17  2020 Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations. AML, ET, MPN, PMF
18  2020 Molecular genetics of MDS/MPN overlap syndromes. ---
19  2020 Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment. ---
20  2020 Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? ---
21  2020 Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? ---
22  2020 NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? AML, MDS, MNs
23  2020 NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML. ---
24  2020 Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019. MDS
25  2020 Update on CML-Like Disorders. aCML, CEL-NOS, CML, CMML, CNL, SM-AHN
26  2020 [Essential thrombocythemia correctly diagnosed through the guidance of comprehensive genomic profiling]. ---
27  2020 [Relapsed acute myeloid leukemia concomitant with TET2-mutated peripheral T-cell lymphoma, not otherwise specified]. AML, BM, PTCL-NOS
28  2020 [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies]. CCUS, ICUS, MDS
29  2019 "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows". BM, FCM, MDS, SS
30  2019 Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. CIR, MDS, NMA, NRM, OS, RIC
31  2019 Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms. allo-HSCT, BU, CMML, CY, DEC, Flu, GVHD, MDS, OS
32  2019 Gender disparity in the survival of patients with primary myelodysplastic syndrome. MDS, RA, RCMD, SEER
33  2019 Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. CHIP, CMML
34  2019 Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. MDS
35  2019 Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications. ---
36  2019 Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis. ---
37  2019 NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. MDS, SCT
38  2019 [Genomic aberrations in myelodysplastic syndromes and related disorders]. MDS, sAML
39  2018 Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. CGC, CMA, CN-LOH, CNAs, MDS, MPN
40  2018 Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. SNP
41  2018 Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). ---
42  2018 Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study. IADs
43  2018 Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. BM, SIPA1
44  2018 [FGFR1-mutated B-cell acute lymphoblastic leukemia transforming to myelodysplastic / myeloproliferative neoplasm and acute myeloid leukemia]. ALL, AML, FGFR1, FISH, Ph
45  2018 [Myelodysplastic/myeloproliferative neoplasm: a histopathological review]. ---
46  2017 Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. aCML, idicX, iX
47  2017 Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. AML, HMA, LDH, mRUNX1
48  2017 Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. ---
49  2017 Somatic SETBP1 mutations in myeloid neoplasms. sAML
50  2017 The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms. ---
51  2017 Turning the tide in myelodysplastic/myeloproliferative neoplasms. ---
52  2016 Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. allo-HSCT, CIR, NRM, OS
53  2016 An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. aCML, CMML, JMML, RARS-T, WHO
54  2016 Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. BM, FCI, HMAs, HSCT, MDS
55  2016 Proactive Consultation by a Clinical Pathologist Prevents Diagnostic Delay in Hematological Malignancies. CLL, MM, PCCP
56  2016 Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. MDS, NMD, RARS
57  2016 Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms. WHO
58  2016 Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. FFPE, MDS
59  2016 Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. PI3K
60  2016 Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Akt, GM-CSF, JMML, MAPK
61  2016 [Chronic Myelomonocytic Leukemia with Myelofibrosis Resulting in Sudden Massive Pleural Effusion during Cytoreductive Therapy with Hydroxycarbamide]. CMML
62  2015 A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide. ---
63  2015 An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. MDS, MPN
64  2015 An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report. RARS-T
65  2015 DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies. ctDNA, NSCLC
66  2015 Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. CMML, IMCs
67  2015 Reassessment of H&E stained clot specimens and immunohistochemistry of phosphorylated Stat5 for histological diagnosis of MDS/MPN. aCML, CMML, JMML, MDS
68  2014 Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). allo-SCT, AML, LFS, SFGM-TC
69  2014 Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. aCML
70  2014 Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. JMML
71  2014 Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients. AML-MRC, AML-NOS, CR, DFS, MDS, MLD, OS
72  2014 Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. MDS
73  2014 Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. AML, CMML, CN-LOH, ET, MC, MF, MPN, MPN-U, PV, SNP-A
74  2014 I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. aCML, CMML, RARS-T
75  2014 Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. aCML, CMML, JMML, RARS-T
76  2014 Nosocomial infection in adult admissions with hematological malignancies originating from different lineages: a prospective observational study. AML, HM, LN, MN, NI
77  2013 A transient myelodysplastic/myeloproliferative neoplasm in a patient with cardio-facio-cutaneous syndrome and a germline BRAF mutation. CFC
78  2013 Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. aCML, CMML, HCT, MAC, RIC
79  2013 Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. MFC, RARS-T
80  2013 Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. NGS
81  2012 Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. aCML, CMML
82  2012 Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. AML, CDKN2A, CDKN2B, IPSS, MDS, MS-MLPA, WHO
83  2012 [The classification and therapy of myelodysplastic/myeloproliferative neoplasms (MDS/MPN)]. ---
84  2011 A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). JAK2, PMF, TADA, TET2
85  2011 Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. AML, MDS
86  2011 Myelodysplastic/myeloproliferative neoplasms. CMML, JMML, MDS, MPN, RARS-T, WHO
87  2011 Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. AML
88  2011 Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings. RARS-T
89  2010 ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. aCGH, CMML
90  2010 Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. AML, CDR, CN-LOH, CRR, MC, MDS, SNP-A
91  2010 Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders. aCML, CMML, JMML, MDS, MPN, RARS-T
92  2010 Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. PCR
93  2009 Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification. FGFR1, MDS, MPN
94  2009 Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? ET, RARS-T, WHO
95  2009 The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. AML, MDS, MPNs, WHO